TABLE 2.
Baseline parameters in patients receiving no RAAS inhibitors for different PP quartiles
| PP < 46.2 mmHg | PP 46.2 ‐ 57.0 mmHg | PP 57.0 ‐ 69.3 mmHg | PP > 69.3 mmHg | |||
|---|---|---|---|---|---|---|
| Variable | (N = 360) | (N = 355) | (N = 348) | (N = 353) | P* | P. linear** |
| Age (years) | 54(10.4) | 58.4(11) | 62.5(9.89) | 68.5(8.69) | <0.001 | <0.001 |
| Female sex (%) | 34.2 | 27.3 | 31.6 | 35.4 | 0.101 | 0.477 |
| BMI (kg/m2) | 26.5(3.77) | 26.7(3.52) | 27.3(3.47) | 27.2(3.66) | 0.002 | 0.002 |
| LDL‐C (mg/dl) | 121(35.4) | 121(34.6) | 122(35.5) | 116(35.3) | 0.086 | 0.085 |
| HDL‐C (mg/dl) | 40.3(10.5) | 40.2(10.7) | 40.3(11.1) | 40(11.6) | 0.704 | 0.704 |
| TG (mg/dl) | 144(101‐199) | 146(110‐202) | 142(109‐201) | 144(101‐199) | 0.530 | 0.530 |
| SBP (mmHg) | 116(11.8) | 131(11.1) | 145(10.5) | 165(15.7) | <0.001 | <0.001 |
| DBP (mmHg) | 77.1(10.5) | 79.6(10.5) | 82.1(9.65) | 83.4(11.5) | <0.001 | <0.001 |
| Creatinine | 0.945(0.568) | 0.933(0.324) | 0.938(0.308) | 0.997(0.586) | 0.143 | 0.143 |
| Cystatin C | 0.9(0.41) | 0.909(0.42) | 0.924(0.31) | 1.02(0.433) | <0.001 | <0.001 |
| Uromodulin | 181(82.2) | 175(78) | 172(75.8) | 155(71.1) | <0.001 | <0.001 |
| central PP | 58.1(15.3) | 61.9(16.1) | 72.6(17.7) | 83.9(18.9) | <0.001 | <0.001 |
| PP | 39.1(5.46) | 51.6(3.07) | 62.5(3.33) | 81.5(11) | <0.001 | <0.001 |
| DP | 7910(1700) | 9020(1930) | 9850(1790) | 11400(2410) | <0.001 | <0.001 |
| MAP | 90.2(10.6) | 96.8(10.6) | 103(9.81) | 111(12) | <0.001 | <0.001 |
| Renin (pg/ml) | 10.8(5.99‐19.8) | 9.58(5.39‐16.8) | 8.38(4.79‐14.4) | 7.78(4.79‐13.8) | <0.001 | <0.001 |
| Aldosterone (ng/l) | 83.5(52‐125) | 90(56‐131) | 80(49.2‐123) | 80(50.2‐121) | 0.074 | 0.073 |
| Angiotensinogen (nnmol/l) | 1190(905‐1490) | 1170(942‐1470) | 1230(965‐1580) | 1210(971‐1540) | 0.056 | 0.056 |
| Angiotensin‐I (ng/l) | 1540(1170‐1930) | 1510(1220‐1900) | 1590(1250‐2040) | 1560(1260‐2000) | 0.055 | 0.055 |
| Angiotensin‐II (ng/l) | 20(13‐33.2) | 18(12‐32) | 20(12‐31) | 18.5(12‐34) | 0.115 | 0.115 |
| ACE (U/l) | 32(24‐40) | 30(24‐38.5) | 30(23‐38) | 29(22‐40) | 0.003 | 0.003 |
| Adrenalin (ng/l) | 33(20‐51) | 33.5(21‐51) | 39(24‐60) | 39(23‐64) | 0.001 | 0.001 |
| Noradrenalin (ng/l) | 256(185‐384) | 278(196‐403) | 302(216‐419) | 324(236‐460) | <0.001 | <0.001 |
| Aldosterone / Renin | 4.43(2.5‐7.76) | 5.24(2.88‐8.85) | 5.48(2.99‐10.2) | 5.65(2.82‐10.4) | 0.001 | 0.001 |
| NT‐proBNP (pg/mL) | 131(51.2‐334) | 125(58‐352) | 170(79.2‐414) | 310(130‐756) | <0.001 | <0.001 |
| Coronary artery disease (%) | 58.6 | 65.6 | 70.4 | 81 | <0.001 | <0.001 |
| Diabetes mellitus (%) | 21.9 | 30.4 | 31.6 | 46.7 | <0.001 | <0.001 |
| Smoking (current or ex, %) | 68.1 | 65.4 | 63.2 | 54.4 | 0.001 | <0.001 |
*ANOVA for continuous variables, non‐normally distributed variables were log‐transformed before entering analyses, and chi‐square test for categorical variables; ** Linear trend, for categorical variable the Cochrane‐Armitage test was used.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; DP, double product; MAP, mean arterial pressure; ACE, angiotensin Converting Enzyme; CAD: Coronary artery disease.